Skip to main content

Table 2 Outcomes per cohort of 1000 critically ill patients with suspected nosocomial candidemia

From: Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation

Outcome Point estimate 95% confidence interval*
Empiric MIC compared with empiric FLU   
   Deaths averted 4 2 to 13
   Incremental cost/death averted† $61,446 $43,821 to $80,039
   Incremental cost/life year saved†¶ $22,230 $18,201 to $26,088
   Incremental cost/QALY†¶ $34,734 $26,312 to $49,209
Empiric MIC compared with watchful waiting strategy   
   Deaths averted 29 11 to 69
   Incremental cost/death averted† $9,892 $3,771 to $26,065
   Incremental cost/life year saved†¶ $17,777 $14,174 to $21,360
   Incremental cost/QALY†¶ $27,777 $20,572 to $39,888
Empiric FLU compared with watchful waiting strategy   
   Deaths averted 25 9 to 57
   Incremental cost/death averted† $1,704 $640 to $4,839
   Incremental cost/life year saved†¶ $17,070 $13,582 to $20,436
   Incremental cost/QALY†¶ $26,672 $19,699 to $38,223
  1. *From the Monte Carlo simulations, 10,000 trials for each outcome.
  2. †All costs inflated to 2008 $US using medical component of the consumer price index.
  3. Costs incorporating lifetime estimates are discounted at 3% per annum (range 0 to 6%)
  4. FLU = fluconazole; MIC = micafungin; QALY = quality-adjusted life year.
Back to article page

Critical Care

ISSN: 1364-8535